← board
PTGX
Protagonist Therapeutics, Inc.distress 0/10 · well-funded / low risk$134.44-1%today-5% from 52w high
Hematology 2
Lead: Obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$620M
Runway
5.3 yrs
Shares 1y
+3%
Price & events
+58.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
+1.8%
1W
+13.0%
1M
+31.0%
3M
+61.8%
6M
+148.1%
1Y
+251.5%
2Y
+185.9%
5Y
+585.9%
All
Overview
- Market Cap
- $8.65B
- Volume
- 67.16K
- 52 Week Range
- $50.96 – $141
- Total Shares
- 64.31M
- Float Shares
- 52.49M
- Short %
- 13.91%
- % Held by Insiders
- 0.71%
- % Held by Institutions
- 125.33%
- RVOL
- 0.08x
- Beta
- 1.79
Pipeline stages · 3 programs
Open-label rusfertide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Rusfertide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PN-881 Oral Solution, PN-881 Oral Tablet
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-15 | Phase 1 | PN-881 Oral Solution, PN-881 Oral Tablet | Healthy Volunteer | 142 | recruiting |
| 2026-04-01 | Phase 3 | Open-label rusfertide | Polycythemia Vera | 46 | active not recruiting |
| 2025-02-21 | Phase 3 | Rusfertideorphanfast track | Polycythemia Vera | 293 | active not recruiting |
Catalyst news & presentations · 7
- 2H '26Guided 55%trial initiationsecondaryPhase 1PN-477o · Phase 1 initiation for daily oral triple agonistSEC 8-K
- 2026-08-06earningsEarningsEarnings releaseyahoo
- Mid '26trial initiationsecondaryPhase 1PN-477sc · Phase 1 initiation for weekly sc triple agonistSEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)icotrokinra · Potential NDA submission for plaque psoriasisSEC 8-K
- first half of 2025readoutPhase 2icotrokinra · Topline results for Phase 2b ANTHEM studySEC 8-K
- March 8, 2025trial initiationsecondaryPhase 3icotrokinra · Initiation of first-ever head-to-head study (ICONIC-ASCEND) comparing icotrokinra vs ustekinumab.SEC 8-K
- 2024-11-18partnershipicotrokinra · Earned $165M milestone payment expected Q1 2025SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $125 (-7% upside) · 13 analysts
- 2026-07-14BarclaysOverweight
- 2026-07-07Truist SecuritiesBuy
- 2026-05-06CitizensMarket Outperform
- 2026-05-06WedbushOutperform
- 2026-04-15Truist SecuritiesBuy
- 2026-04-07Clear StreetBuy
Competitors — Obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-22Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup - ChartMill
- 2026-07-20Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
- 2026-07-20PROTAGONIST THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $155 FROM $100 - Bitget
- 2026-07-20Protagonist Therapeutics stock hits all-time high at 141.79 USD - Investing.com
- 2026-07-20Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
- 2026-07-19Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open - simplywall.st
- 2026-07-19Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open - Sahm
- 2026-07-17Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.